Literature DB >> 23765261

N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience.

A A Kohan1, J A Kolthammer, J L Vercher-Conejero, C Rubbert, S Partovi, R Jones, K A Herrmann, P Faulhaber.   

Abstract

OBJECTIVES: Evaluate the performance of PET/MRI at tissue interfaces with different attenuation values for detecting lymph node (LN) metastases and for accurately measuring maximum standardised uptake values (SUVmax) in lung cancer patients. MATERIALS AND
METHOD: Eleven patients underwent PET/CT and PET/MRI for staging, restaging or follow-up of suspected or known lung cancer. Four experienced readers determined the N stage of the patients for each imaging method in a randomised blinded way. Concerning metastases, SUVmax of FDG-avid LNs were measured in PET/CT and PET/MRI in all patients. A standard of reference was created with a fifth experienced independent reader in combination with a chart review. Results were analysed to determine interobserver agreement, SUVmax correlation between CT and MRI (three-segment model) attenuation correction and diagnostic performance of the two techniques.
RESULTS: Overall interobserver agreement was high (κ = 0.86) for PET/CT and substantial (κ = 0.70) for PET/MRI. SUVmax showed strong positive correlation (Spearman's correlation coefficient = 0.93, P < 0.001) between the two techniques. Diagnostic performance of PET/MRI was slightly inferior to that of PET/CT, without statistical significance (P > 0.05).
CONCLUSIONS: PET/MRI using three-segment model attenuation correction for LN staging in lung cancer shows a strong parallel to PET/CT in terms of SUVmax, interobserver agreement and diagnostic performance. KEY POINTS: •F18-FDG PET/MRI shows similar performance to F18-FDG PET/CT in lung cancer N staging. •PET/MRI has substantial interobserver agreement in N staging. •A three-segment model attenuation correction is reliable for assessing the mediastinum.

Entities:  

Mesh:

Year:  2013        PMID: 23765261     DOI: 10.1007/s00330-013-2914-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  21 in total

Review 1.  Correlation and simple linear regression.

Authors:  Kelly H Zou; Kemal Tuncali; Stuart G Silverman
Journal:  Radiology       Date:  2003-06       Impact factor: 11.105

2.  Understanding interobserver agreement: the kappa statistic.

Authors:  Anthony J Viera; Joanne M Garrett
Journal:  Fam Med       Date:  2005-05       Impact factor: 1.756

3.  Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT.

Authors:  Marco Wiesmüller; Harald H Quick; Bharath Navalpakkam; Michael M Lell; Michael Uder; Philipp Ritt; Daniela Schmidt; Michael Beck; Torsten Kuwert; Carl C von Gall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-06       Impact factor: 9.236

4.  Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.

Authors:  Xiaolin Li; Huaqi Zhang; Ligang Xing; Honglian Ma; Peng Xie; Lin Zhang; Xiangying Xu; Jinbo Yue; Xindong Sun; Xudong Hu; Ming Chen; Wengui Xu; Lusheng Chen; Jinming Yu
Journal:  Radiother Oncol       Date:  2011-11-17       Impact factor: 6.280

Review 5.  Staging of non-small cell lung cancer (NSCLC): a review.

Authors:  S Tsim; C A O'Dowd; R Milroy; S Davidson
Journal:  Respir Med       Date:  2010-09-15       Impact factor: 3.415

6.  Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction.

Authors:  Georg Schramm; Jens Langner; Frank Hofheinz; Jan Petr; Bettina Beuthien-Baumann; Ivan Platzek; Jörg Steinbach; Jörg Kotzerke; Jörg van den Hoff
Journal:  MAGMA       Date:  2012-08-26       Impact factor: 2.310

7.  Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.

Authors:  Philipp Heusch; Christian Buchbender; Karsten Beiderwellen; Felix Nensa; Verena Hartung-Knemeyer; Thomas C Lauenstein; Andreas Bockisch; Michael Forsting; Gerald Antoch; Till A Heusner
Journal:  Eur J Radiol       Date:  2013-02-08       Impact factor: 3.528

8.  Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.

Authors:  Hiroaki Nomori; Takeshi Mori; Koei Ikeda; Koichi Kawanaka; Shinya Shiraishi; Kazuhiro Katahira; Yasuyuki Yamashita
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

9.  ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer.

Authors:  Paul De Leyn; Didier Lardinois; Paul E Van Schil; Ramon Rami-Porta; Bernward Passlick; Marcin Zielinski; David A Waller; Tony Lerut; Walter Weder
Journal:  Eur J Cardiothorac Surg       Date:  2007-04-19       Impact factor: 4.191

10.  Whole-body PET/CT scanning: estimation of radiation dose and cancer risk.

Authors:  Bingsheng Huang; Martin Wai-Ming Law; Pek-Lan Khong
Journal:  Radiology       Date:  2009-02-27       Impact factor: 11.105

View more
  15 in total

1.  Magnetic resonance imaging for staging of non-small-cell lung cancer-technical advances and unmet needs.

Authors:  Gregor Sommer; Bram Stieltjes
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

Review 2.  Evaluation of lymph node metastasis in lung cancer: who is the chief justice?

Authors:  Yang Xia; Bin Zhang; Hao Zhang; Wen Li; Ko-Pen Wang; Huahao Shen
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

3.  Thoracic staging of non-small-cell lung cancer using integrated (18)F-FDG PET/MR imaging: diagnostic value of different MR sequences.

Authors:  Benedikt Schaarschmidt; Christian Buchbender; Benedikt Gomez; Christian Rubbert; Florian Hild; Jens Köhler; Johannes Grueneisen; Henning Reis; Verena Ruhlmann; Axel Wetter; Harald H Quick; Gerald Antoch; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-08       Impact factor: 9.236

4.  Quantitative carotid PET/MR imaging: clinical evaluation of MR-Attenuation correction versus CT-Attenuation correction in (18)F-FDG PET/MR emission data and comparison to PET/CT.

Authors:  Jason Bini; Philip M Robson; Claudia Calcagno; Mootaz Eldib; Zahi A Fayad
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-02-15

Review 5.  Clinical PET-MR Imaging in Breast Cancer and Lung Cancer.

Authors:  Samuel L Rice; Kent P Friedman
Journal:  PET Clin       Date:  2016-10

Review 6.  FDG Whole-Body PET/MRI in Oncology: a Systematic Review.

Authors:  Hyun Woo Kwon; Ann-Katharina Becker; Jin Mo Goo; Gi Jeong Cheon
Journal:  Nucl Med Mol Imaging       Date:  2016-04-07

7.  Optimized workflow and imaging protocols for whole-body oncologic PET/MRI.

Authors:  Shirou Ishii; Takamitsu Hara; Takeyuki Nanbu; Hiroki Suenaga; Shigeyasu Sugawara; Daichi Kuroiwa; Hirofumi Sekino; Masayuki Miyajima; Hitoshi Kubo; Noboru Oriuchi; Hiroshi Ito
Journal:  Jpn J Radiol       Date:  2016-10-06       Impact factor: 2.374

Review 8.  MR Imaging-Guided Attenuation Correction of PET Data in PET/MR Imaging.

Authors:  David Izquierdo-Garcia; Ciprian Catana
Journal:  PET Clin       Date:  2016-01-26

Review 9.  Clinical applications of PET/MRI: current status and future perspectives.

Authors:  Felix Nensa; Karsten Beiderwellen; Philipp Heusch; Axel Wetter
Journal:  Diagn Interv Radiol       Date:  2014 Sep-Oct       Impact factor: 2.630

10.  Pulmonary Nodule Detection in Patients with a Primary Malignancy Using Hybrid PET/MRI: Is There Value in Adding Contrast-Enhanced MR Imaging?

Authors:  Kyung Hee Lee; Chang Min Park; Sang Min Lee; Jeong Min Lee; Jeong Yeon Cho; Jin Chul Paeng; Su Yeon Ahn; Jin Mo Goo
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.